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INTRODUCTION
The tumor cells of blastic NK cell lymphoma (Blastic NKL)
express CD56 antigen with no obvious evidence of B- or T-
cell differentiation and some cases expressing CD4 and TdT.
Committed natural killer (NK) cell has been postulated as a
cell of origin, because CD56 (NCAM) is useful marker in
detecting NK-related cells (1). However, CD56 is not lineage-
specific, and its aberrant expression also has been identified in
a variety of unrelated hematopoietic malignancies including
acute myeloid leukemia with myelomonocytic differentiation
and other immature hematopoietic neoplasms of undefined
origin. The results of recent studies challenged the terminol-
ogy ‘‘blastic natural killer cell lymphoma’’ and support that
blastic NKL is a tumor of plasmacytoid dendritic cells, not
of NK progenitors (2). Herein we report 4 CD56+ CD4+ non-
B, non-T, non-myeloid neoplasms with blastoid morphology.
CASE REPORTS
Case 1 
A 45-yr-old man presented with multiple subcutaneous
masses in the left upper and lower extremities. At that time,
neither lymph nodal involvement nor leukemia was detected.
The patient received 6 cycles of CHOP (cyclophosphamide,
adriamycin, vincristine, prednisolone) and IMVP-16 (ifos-
famide, methotrexate, etoposide, prednisolone), but the dis-
ease progressed. Multiple subcutaneous masses and lymph
nodal invasion developed in 10 and 21 months after the first
visit. He received adjuvant radiation therapy, but leukemic
transformation (blast, 34% in peripheral blood smear) and
brain involvement also occurred in 23 and 27 months after
initial presentation, respectively. In spite of further chemother-
apy with daunorubicin, Ara-C (cytosine arabinoside), vincris-
tine and prednisolone as well as intrathecal chemotherapy, he
died of sepsis 28 months after the diagnosis.
Case 2
A 17-yr-old girl presented with multiple bluish and pur-
puric maculopatches on the upper and lower extremities and
back, and a deep subcutaneous nodule for 2 months. Initial
hematological findings were within normal limit. The patient
was transferred to another hospital and further follow-up re-
sults were not available.
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CD4+CD56+ Lineage Negative Hematopoietic Neoplasm
: So Called Blastic NK Cell Lymphoma
Blastic natural killer (NK) cell lymphoma is a rare neoplasm characterized by blastoid
tumor cells expressing CD4 and CD56, with predominant skin involvement. Although
this tumor has been regarded as a neoplasm related to NK cell, recent studies sug-
gested that it is derived from plasmacytoid dendritic cells, but not from NK cell. Herein
we report 4 cases of CD4+CD56+ lineage marker- blastic NK cell lymphomas with
a review of literatures. The patients were 3 men and one woman. Three of them were
young (17, 18, and 22 yr old). Three patients had skin lesions, at initial presentation
in two patients and during the course of disease in other patient. Histologically, tumors
consisted of monotonous medium to large blastoid cells showing no necrosis, angio-
centric growth or epidermotrophism. All four tumors were CD4+ and CD56+. Three
expressed CD68 antigen. Lineage specific markers for B- and T cell were negative.
All tumors did not express myeloperoxidase. T-cell receptor gene rearrangement,
EBV, CD13 and CD33 were negative. In one patient, tumor cells arranged in Homer-
Wright type pseudorosette and expressed terminal deoxynucleotidyl transferase
(TdT). Despite the standard lymphoma chemotherapy, the tumors, except one lost
during follow-up, progressed and relapsed. The patients died 8-60 months after
diagnosis. 
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Case 3 (reported in 1998, reference 3)
An 18-yr-old man was admitted with left inguinal lympha-
denopathy, night sweat and weight loss. A computed tomo-
graphic scan of the abdomen revealed splenomegaly and the
enlarged left para-aortic lymph nodes. Peripheral blood find-
ings were as follows: hemoglobin (Hb) 15.5 g/dL; white
blood cells (WBC) 5.4×103/ L; normal differential counts
except increased monocytes (10.2%). The level of LDH (261
IU/L) and AST (144 U/L) increased. Bone marrow aspiration
and biopsy showed no abnormal findings. He received 3 cycles
of CHOP chemotherapy. Three months later, a cutaneous
nodule in the left thigh developed. Subsequently he received
additional 5 cycles of CHOP chemotherapy. Complete remis-
sion was achieved for 2 yr until he suffered from left mandibu-
lar pain. Extraction of a wisdom tooth followed by biopsy of
the gum revealed atypical lymphoid infiltration. Two months
later, he complained of headache and weight loss of 4 kg. On
physical examination, protrusion of the right eyeball and en-
largement of right neck lymph nodes were found. He was
anemic (Hb 5.6 g/dL, Hct 15.7%, reticulocytes 0.08%) and
had severe thrombocytopenia (93,000/ L) and leukopenia
(480/ L). A computed tomographic scan of the head and neck
showed a relatively well demarcated tumor in the right eth-
moid sinus which extended into the right orbit, and the max-
illary and frontal sinuses. Bone marrow biopsy was positive.
Chemotherapy with IMVP-16 regimen was started. He died
60 months after the diagnosis.
Case 4 (reported in 2002, reference 4)
A 22 yr-old male patient was admitted with the multiple
lymphadenopathy of the  inguinal, cervical, and preauricular
lymph nodes, the largest of them measuring 4 cm in diame-
ter. A computed tomographic scan of the abdomen revealed
diffuse hepatosplenomegaly and the enlarged paraaortic, com-
mon iliac, and external iliac lymph nodes. Peripheral blood
findings were as follows: Hb 15.3 g/dL; WBC 7.4×103/L ;
normal differential except increased monocytes (8.2%). The
level of LDH (676 IU/L) increased. The bone marrow was
positive. After biopsy of the cervical lymph node, he received
one cycle of CHOP chemotherapy without response. Then
high dose CHOP chemotherapy was given with achievement
of complete remission. Subsequently the patient underwent
peripheral blood stem cell transplantation, however, the tumor
recurred in the bone marrow four months later. 
Histopathology
Tumors of all four cases displayed similar appearance and
were composed of diffuse infiltration of monotonous medi-
um-to-large blastoid cells. Nuclei of three cases showed fine
chromatin and inconspicuous nucleoli. Tumor cells of Case 4
exhibited prominent nucleoli simulating immunoblast. In
skin biopsy, dense infiltration of tumor cells without necrosis
or angiocentric growth was noted in the upper and mid-der-
mis and occasionally in the dermis to the subcutaneous tissue
(Fig. 1). Mitoses were rather variable. The tumor cells exhib-
ited no epidermotrophism. Biopsy of lymph nodes showed
effacement of nodal architecture by diffuse proliferation of
monomorphic lymphoid cells. Peculiarly, in Case 3, tumor
cells were arranged around a central fibrillary core, which was
very similar to Homer-Wright type pseudorosettes seen in
neuroepithelial tumors (Fig. 2A). Touch imprint with Giemsa
Fig. 1. Histologic finding of the skin biopsy (Case 1), dense infiltration of medium-sized blastoid tumor cells without necrosis or angiocen-
tric growth noted in the upper and mid-dermis without epidermotrophism (H&E stain, A; ×100, B; ×250).
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stain revealed no cytoplasmic azurophilic granules. 
Immunohistochemial findings and main clinical informa-
tion of these cases are summarized in Table 1. CD2 (Novocas-
tra, U.K.), CD3 (Novocastra, U.K.), CD4 (Novocastra, U.K.),
CD5 (Novocastra, U.K.), CD7 (Novocastra, U.K.), CD8 (No-
vocastra, U.K.), CD20 (Novocastra, U.K.), CD30 (Dako, De-
nmark), CD34 (Dako, Denmark), CD43 (Serotechs, Bethes-
da, MD), CD56 (Monosan, The Netherland), CD68 (Dako),
CD79a (Dako), terminal deoxynucleotidyl transferase (TdT,
Dako), myeloperoxidase (Dako), TIA-1 (Immunotech, West-
brook, ME), lysozyme (Zymed, U.S.A.) were used in the pre-
sent study. All four tumors were CD4+/CD56+ (Fig. 3). Only
Case 3 tumor displayed positive reactivity for TdT (Fig. 2B).
All four tumors were negative for myeloperoxidase. As for
CD68, three cases were positive, while Case 3 was negative.
Flow cytometric analysis was performed in Case 3 and 4.
Myeloid markers (CD13, CD33) were negative. EBV in situ
hybridization was performed using the fluorescein-conjugated
EBER1 and 2 oligonucleotides (Dako, Denmark). Briefly,
paraffin sections were pretreated with xylene, followed by the
Fig. 2. In Case 3, tumor cells arranged in Homer-Wright type pseudorosette (A; H&E stain, ×400) with positivity for terminal deoxynucleotidyl
transferase (B; ×400).
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Fig. 3. Results of immunohistochemical stains. Most of tumor cells strongly express CD56 (A) and CD4 (B) (×400).
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treatment with proteinase K and finally hybridized with EBV
oligonucleotides. As negative controls we used EBV-negative
lymphoid tissues and the hybridization mixture without the
EBV oligonucleotides. The results were all negative.
For polymerase chain reaction amplification of the T-cell
receptor (TCR) gamma gene, DNA was prepared by standard
proteinase K digestion and phenol/chloroform extraction. PCR
followed by SSCP analysis was performed as described previ-
ously (5). No clonal rearrangement of TCR gene was demon-
strated in all four cases.
DISCUSSION
Blastic NK cell lymphoma has been described under the
various names including lymphoblastic lymphoma of NK
phenotype, blastoid NK cell lymphoma, and leukemic lym-
phoma of immature NK lineage, and recently defined as a
distinct entity of unknown cellular origin in the new World
Health Organization classification (1). The neoplastic cells
are negative for surface CD3 and are positive for CD56. CD4
is usually expressed. CD68 is generally negative, or only weakly
and focally expressed. Expression of CD2, cytoplasmic CD3 ,
and cytotoxic molecules is variable, but usually negative. Some
cases are TdT and/or CD34-positive. Diagnosis of blastic
NKL can be made in the absence of commitment to the B-,
T-cell or myeloid lineage. Thus the tumor should be negative
for TCR gene rearrangement, surface CD3, myeloperoxidase,
CD13 and CD33 (1). In the present study, all cases showed
blastoid morphology and expressed CD56 and CD4 with
absence of myeloperoxidase expression and TCR gene rear-
rangement, thus fulfilling the minimum criteria of blastic
NKL in the current WHO classification. Similar to previous
reports, two cases presented with skin lesions, but the others
presented with lymphadenopathy. TdT expression was noted
in only one case. 
These blastic NKL raises two interesting questions. First,
is the term, blastic NKL, appropriate to define these CD4+
CD56+ lineage-negative blastoid neoplasms? Second, what
is the pathogenetic implication of TdT expression in blastic
NKL?
In the normal developmental pathway of NK cells, pre-NK
cells express CD161, immature NK cells express CD161 and
CD56, and mature NK cells express CD161, CD56 and CD94.
Whereas aggressive NK-cell leukaemia/lymphoma and nasal
NK-cell lymphoma, express both CD56 and CD94 with
strong NK activity, tumor cells of blastic NKL lack CD94
and CD161 and express CD56 only (6). That is, blastic NKL
does not express any of these mature or immature NK-related
markers except CD56. CD56 is not NK-lineage specific mar-
ker but often expressed on various types of neoplasia that are
not of NK lineage (6). The only presence of CD56 without
other evidence of NK lineage is not sufficient to support the
notion that those tumors are of NK blast. Hence, some authors
have objected to the term ‘‘Blastic NK lymphoma’’ and pro-
posed other name about these CD56+ CD4+ non-B, non-T
neoplasms.
The term ‘‘CD56 positive undifferentiated acute leukemia’’
was suggested by Almasri et al. who denied NK cell origin
for this tumor because CD4 is not expressed on normal fetal
or adult NK cells (7). On the other hand, Petrella et al. pro-
posed ‘‘CD4+CD56+ hematodermic neoplasm’’, because these
Case 1  Case 2 Case 3* Case 4
�
Age (yr)/ Sex 45/ Male 17/ Female 18/ Male 22/ Male
Presenting symptoms Skin, nodules Skin, purpuric patches Multiple lymphadenopathy,  Systemic lymphadenopathy
B-symptoms
Other involved sites Lymph nodes, bone  Spleen, skin, bone marrow Liver, spleen, bone marrow
marrow, brain
Treatment CHOP and IMVP-16, radiation,  CHOP and IMVP-16 CHOP
intrathecal chemotherapy Bone marrow transplantation
Outcome Died of sepsis (28 months  Lost to follow-up Died of sepsis (60 months  Died of sepsis (8 months 
after diagnosis) after diagnosis) after diagnosis)
Paraffin tissue  cCD3-/CD56+/CD4+/  cCD3-/CD56+/CD4+/ cCD3-/CD4+/CD34-/ CD45+/CD4+/CD56+/
immunohistoche- TdT-/MPO-/TIA-1-/ TdT-/MPO-/TIA-1-/  CD43+/CD56+/ CD68+/TdT-/MPO-/
mical stain CD5-/CD20-/CD30-/ CD20-/CD79a-/  CD68-/ TdT+/ TIA-1-/CD20-/CD30-
CD43+/CD79a-/ CD68focal+ MPO-/ TIA-1 CD43-/CD45RA-/S100-/CD1a-
CD68weak+/lysozyme-
Flow cytometry CD2-/sCD3-/ CD2-/cCD3+/CD5-/
cCD3weak+/CD7-/ CD7-/ CD10+/ CD13-/
CD8-/CD13-/CD16+/ CD14-/CD19-/TdT-/
CD20-/CD33- CD33-/CD34-/HLA-DR+/TdT-
TCR /EBER TCR -/EBER - TCR -/EBER - TCR -/EBER - TCR -/EBER -
Table 1. Summary of clinical data and results of immunohistochemical and other studies
TCR, polymerase chain reaction amplification of the T-cell receptor gamma gene; EBER, EBV in situ hybridization; TdT, terminal deoxynucleotidyl trans-
ferase; MPO, myeloperoxidase. *reported in 1998, reference 3, 
�
reported in 2002, reference 4.neoplasms mainly involve the skin (2). In addition, they assert-
ed that CD4+CD56+ hematodermic neoplasm is a tumor of
plasmacytoid dendritic cell (pDC) (2). Likewise Jacob et al.
proposed ‘‘early plasmacytoid dendritic cell leukemia/lym-
phoma’’ for those CD4+CD56+ lineage-negative neoplasm
(8). 
Recently, Karube et al. divided non-B, non-T (lineage neg-
ative) neoplasms with lymphoblastic morphology into four
types based on immunohistochemistry. They are 1) CD7+
stem cell lymphoma [CD4-, CD7+, CD33+/-, CD56-], 2)
blastic NKL [CD4-, CD7+/-, CD33-, CD56+, CD123-], 3)
myeloid/NK precursor cell leukemia [CD4-, CD7+, CD33+,
CD56+], and 4) CD4+CD56+ hematodermic malignancy
[CD4+, CD7+/-, CD33-, CD56+, CD123+]. Based on dif-
ferences of clinical and phenotypical features, they contended
that ‘‘CD4-56+ blastic NKL’’ is clearly distinct from CD4+
CD56+ hematodermic neoplasm (9). 
pDC is an immature dendritic cell, and represents the key
effector cells in the early antiviral innate immune response
by producing large amounts of IFN- / ‚ upon viral infection.
pDC induces CD13, CD33, and CD11c myeloid antigens
when cultured in GM-CSF or IL-3. This lineage conversion
supports the potential of pDCs to differentiate to myeloid
lineage as observed in occasional development of acute mye-
lomonocytic leukemia following cutaneous ‘‘blastic NKL’’ (10).
Another issue in blastic NKL is an expression of TdT in
some but not all the cases. In the blastic NKLs reported pre-
viously, TdT was expressed in 19 of 31 CD4+CD56+ cases
and 14 of 15 CD4-CD56+ cases (3, 9-24). In the study by
Petrella et al. (2), all the 14 CD4+CD56+CD123+ hema-
todermic neoplasms were negative for TdT. Herling et al.
showed 7 cases of CD4+CD56+CD123+ plasmacytoid
dendritic cell tumors expressing TdT in variable patterns,
and two of their patients had transformation to myelomono-
cytic leukemia (25). TdT is a marker for lymphoid blast and
expressed in B- and T-lymphoblastic lymphoma, acute lym-
phoblastic leukemia, and lymphoblastic crisis of chronic mye-
logenous leukemia. Generally TdT is not expressed in cells
of non-lymphoid malignancy, although approximately 20%
of acute myeloid leukemia have TdT+ blasts, some of them
express both myeloid markers and TdT. Even though there
have been no data regarding TdT expression in normal pre-
cursors of NK cells and dendritic cells, in vitro studies showed
that T, B, NK, and dendritic cells have a common progenitor
in the extrathymic and thymic tissue (26, 27). In conjunction
with development of myelomonocytic leukemia in some blastic
NKL, expression of TdT in tumor cells suggests that blastic
NKL is basically of multipotent cells which can differentiate
into dendritic cell, myelomonocyte, and lymphoblast of either
T cell or NK cell with the majority committed to plasmacy-
toid dendritic cell. 
Histologically, our Case 3 exhibited rosette-like appearance.
Homer-Wright rosettes consisting of neoplastic cells sur-
rounding an eosinophilic fibrillary center without a lumen,
is an important finding favoring a neuroepithelial tumor in
the differential diagnosis of small round cell malignancy. In
the malignant lymphoma, rosette-formation is a rare finding
and has been reported in only a few cases. 
As for treatment and prognosis, all three cases in the current
study except one lost during follow-up, were treated with agg-
ressive chemotherapy with or without radiation therapy. How-
ever, the outcomes were dismal. All three patients died from
eight to sixty months after diagnosis. Clinical outcomes of
our cases were similar to the known poor prognosis of CD56+
CD4+ non-B, non-T neoplasia reported previously (14, 28).
Some other studies revealed that the patients treated with
allogenic or autologous stem cell transplantation had a sig-
nificantly more favorable prognosis than those treated with
only chemotherapy and radiation therapy. This finding implies
that intensive chemotherapy with stem cell transplantation
might improve the prognosis of these types of blastoid lym-
phomas (8, 9)
In summary, we described clinicopathologic findings of 4
cases CD4+CD56+ non-B, non-T neoplasm (Blastic NKL
by current WHO classification) which are distinct from other
NK/T-cell lymphomas and show characteristic histological
and immunophenotypic findings. Because the term ‘‘blastic
NK cell lymphoma’’ seems to be a misnomer, we are looking
forward to having an appropriate new terminology for this
tumor in next WHO classification.
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